A multicenter single arm biomarker exploration and validation study. Eighty patients with
NSCLC that are eligible for first line chemo-immunotherapy, first line nivolumab/ipilimumab
or 2nd line and beyond PD-(L)1 immunotherapy monotherapy according to EMA label and national
guidelines will be enrolled in this trial. All subjects will undergo a whole body 18F-PD-L1
PET/CT scan before start of nivolumab containing treatment. Patients will continue treatment
until disease progression, withdrawal of patient consent or unacceptable toxicity.
18F-PD-L1 PET/CT scan to predict durable reponse to nivolumab containing treatment in
patients with NSCLC
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.